{
    "organizations": [],
    "uuid": "d928791c16d3a17dfc34ab7485aa28a2b010ffbc",
    "author": "",
    "url": "https://www.reuters.com/article/brief-deinove-signs-license-option-agree/brief-deinove-signs-license-option-agreement-with-redx-pharma-idUSFWN1R30RA",
    "ord_in_thread": 0,
    "title": "BRIEF-Deinove Signs License Option Agreement With Redx Pharma",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 22, 2018 / 7:27 AM / Updated 7 minutes ago BRIEF-Deinove Signs License Option Agreement With Redx Pharma Reuters Staff March 22 (Reuters) - DEINOVE SA: * DEINOVE EXPANDS ITS INNOVATIVE ANTIBIOTIC PORTFOLIO BY SIGNING A LICENSE OPTION AGREEMENT WITH REDX PHARMA * PROGRAM DEVELOPED BY REDX PHARMA FOCUSES ON A NEW CLASS OF ANTIBIOTICS AIMED AT TREATING MOST LETHAL INFECTIONS * DEINOVE ACQUIRES AN OPTION FOR A LICENSE ON A SERIES OF MOLECULES ABOUT TO ENTER PRECLINICAL DEVELOPMENT. * REDX PHARMA ENTRUSTS DEINOVE WITH NEXT STEPS TO OPTIMIZE ITS ANTI-INFECTIVE PROGRAM. Source text for Eikon: Further company coverage: (Gdynia Newsroom)",
    "published": "2018-03-22T09:26:00.000+02:00",
    "crawled": "2018-03-22T09:43:40.043+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "updated",
        "minute",
        "ago",
        "sign",
        "license",
        "option",
        "agreement",
        "redx",
        "pharma",
        "reuters",
        "staff",
        "march",
        "reuters",
        "deinove",
        "sa",
        "deinove",
        "expands",
        "innovative",
        "antibiotic",
        "portfolio",
        "signing",
        "license",
        "option",
        "agreement",
        "redx",
        "pharma",
        "program",
        "developed",
        "redx",
        "pharma",
        "focus",
        "new",
        "class",
        "antibiotic",
        "aimed",
        "treating",
        "lethal",
        "infection",
        "deinove",
        "acquires",
        "option",
        "license",
        "series",
        "molecule",
        "enter",
        "preclinical",
        "development",
        "redx",
        "pharma",
        "entrusts",
        "deinove",
        "next",
        "step",
        "optimize",
        "program",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}